Purple Biotech Ltd.
PPBTHealthcare|Biotechnology|IL
$1.31
+0.06 (+4.80%)
DCF Value
$1.39
Tangible Book / Share
$0.45
Cash / Share
$0.56
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06919666 NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | P1P2 | Active | 29 | Open-label | NT219 |
| NCT04474470 A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck | P1P2 | Completed | 52 | Open-label | NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion |
| NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | Solid Tumor, Non Small Cell Lung Cancer | P1P2 | Completed | 79 | RCT, Open-label | CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion |